Ashu Shah

Closest collaborators

The 25 strongest of 45 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Surinder K. Batra · 13 shared papers, 2021–2026 · strength 2.39
   • Paper Emerging pathways yielding opportunities for future treatments in pancreatic ductal adenocarcinoma. DOI 10.1080/14728222.2025.2507035↗
   • Paper Targeting the DDX3/PAF1 axis enhances chemotherapy efficacy in pancreatic ductal adenocarcinoma. DOI 10.1016/j.canlet.2026.218276↗
   • Paper SLC22A3/OCT3 drives serotonin-mediated stemness in pancreatic cancer. DOI 10.1016/j.celrep.2026.117387↗
2. Moorthy Palanimuthu Ponnusamy · 12 shared papers, 2021–2026 · strength 2.19
   • Paper Emerging pathways yielding opportunities for future treatments in pancreatic ductal adenocarcinoma. DOI 10.1080/14728222.2025.2507035↗
   • Paper Targeting the DDX3/PAF1 axis enhances chemotherapy efficacy in pancreatic ductal adenocarcinoma. DOI 10.1016/j.canlet.2026.218276↗
   • Paper SLC22A3/OCT3 drives serotonin-mediated stemness in pancreatic cancer. DOI 10.1016/j.celrep.2026.117387↗
3. Sanchita Rauth · 10 shared papers, 2021–2026 · strength 1.63
   • Paper Targeting the DDX3/PAF1 axis enhances chemotherapy efficacy in pancreatic ductal adenocarcinoma. DOI 10.1016/j.canlet.2026.218276↗
   • Paper SLC22A3/OCT3 drives serotonin-mediated stemness in pancreatic cancer. DOI 10.1016/j.celrep.2026.117387↗
   • Paper Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma. DOI 10.1016/j.drup.2024.101146↗
4. Pranita Atri · 8 shared papers, 2021–2024 · strength 1.21
   • Paper Secretory Trefoil Factor 1 (TFF1) promotes gemcitabine resistance through chemokine receptor CXCR4 in Pancreatic Ductal… DOI 10.1016/j.canlet.2024.217097↗
   • Paper A Novel HOXA10-Associated 5-Gene-Based Prognostic Signature for Stratification of Short-term Survivors of Pancreatic Du… DOI 10.1158/1078-0432.ccr-23-0825↗
   • Paper Connectivity mapping-based identification of pharmacological inhibitor targeting HDAC6 in aggressive pancreatic ductal … DOI 10.1038/s41698-024-00562-5↗
5. Jesse L. Cox · 6 shared papers, 2021–2026 · strength 1.02
   • Paper SLC22A3/OCT3 drives serotonin-mediated stemness in pancreatic cancer. DOI 10.1016/j.celrep.2026.117387↗
   • Paper Secretory Trefoil Factor 1 (TFF1) promotes gemcitabine resistance through chemokine receptor CXCR4 in Pancreatic Ductal… DOI 10.1016/j.canlet.2024.217097↗
   • Paper A Novel HOXA10-Associated 5-Gene-Based Prognostic Signature for Stratification of Short-term Survivors of Pancreatic Du… DOI 10.1158/1078-0432.ccr-23-0825↗
6. Palanisamy Nallasamy · 5 shared papers, 2021–2026 · strength 0.91
   • Paper Targeting the DDX3/PAF1 axis enhances chemotherapy efficacy in pancreatic ductal adenocarcinoma. DOI 10.1016/j.canlet.2026.218276↗
   • Paper SLC22A3/OCT3 drives serotonin-mediated stemness in pancreatic cancer. DOI 10.1016/j.celrep.2026.117387↗
   • Paper Secretory Trefoil Factor 1 (TFF1) promotes gemcitabine resistance through chemokine receptor CXCR4 in Pancreatic Ductal… DOI 10.1016/j.canlet.2024.217097↗
7. Parthasarathy Seshacharyulu · 5 shared papers, 2021–2026 · strength 0.79
   • Paper Targeting the DDX3/PAF1 axis enhances chemotherapy efficacy in pancreatic ductal adenocarcinoma. DOI 10.1016/j.canlet.2026.218276↗
   • Paper Connectivity mapping-based identification of pharmacological inhibitor targeting HDAC6 in aggressive pancreatic ductal … DOI 10.1038/s41698-024-00562-5↗
   • Paper Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic duct… DOI 10.1016/j.canlet.2022.215922↗
8. Koelina Ganguly · 5 shared papers, 2021–2024 · strength 0.78
   • Paper Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma. DOI 10.1016/j.drup.2024.101146↗
   • Paper Connectivity mapping-based identification of pharmacological inhibitor targeting HDAC6 in aggressive pancreatic ductal … DOI 10.1038/s41698-024-00562-5↗
   • Paper Chemokine-mucinome interplay in shaping the heterogeneous tumor microenvironment of pancreatic cancer. DOI 10.1016/j.semcancer.2022.03.022↗
9. Lynette M. Smith · 5 shared papers, 2021–2024 · strength 0.71
   • Paper A Novel HOXA10-Associated 5-Gene-Based Prognostic Signature for Stratification of Short-term Survivors of Pancreatic Du… DOI 10.1158/1078-0432.ccr-23-0825↗
   • Paper Connectivity mapping-based identification of pharmacological inhibitor targeting HDAC6 in aggressive pancreatic ductal … DOI 10.1038/s41698-024-00562-5↗
   • Paper Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic duct… DOI 10.1016/j.canlet.2022.215922↗
10. Sushil Kumar K · 5 shared papers, 2021–2024 · strength 0.69
    • Paper Connectivity mapping-based identification of pharmacological inhibitor targeting HDAC6 in aggressive pancreatic ductal … DOI 10.1038/s41698-024-00562-5↗
    • Paper Chemokine-mucinome interplay in shaping the heterogeneous tumor microenvironment of pancreatic cancer. DOI 10.1016/j.semcancer.2022.03.022↗
    • Paper Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic duct… DOI 10.1016/j.canlet.2022.215922↗
11. Maneesh Jain · 4 shared papers, 2022–2024 · strength 0.63
    • Paper Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma. DOI 10.1016/j.drup.2024.101146↗
    • Paper Connectivity mapping-based identification of pharmacological inhibitor targeting HDAC6 in aggressive pancreatic ductal … DOI 10.1038/s41698-024-00562-5↗
    • Paper MUC16 Promotes Liver Metastasis of Pancreatic Ductal Adenocarcinoma by Upregulating NRP2-Associated Cell Adhesion. DOI 10.1158/1541-7786.mcr-21-0888↗
12. Saravanakumar Marimuthu · 4 shared papers, 2022–2026 · strength 0.62
    • Paper Targeting the DDX3/PAF1 axis enhances chemotherapy efficacy in pancreatic ductal adenocarcinoma. DOI 10.1016/j.canlet.2026.218276↗
    • Paper MUC16 Promotes Liver Metastasis of Pancreatic Ductal Adenocarcinoma by Upregulating NRP2-Associated Cell Adhesion. DOI 10.1158/1541-7786.mcr-21-0888↗
    • Paper Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic duct… DOI 10.1016/j.canlet.2022.215922↗
13. Sushil Kumar · 3 shared papers, 2021–2024 · strength 0.52
    • Paper Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma. DOI 10.1016/j.drup.2024.101146↗
    • Paper Secretory Trefoil Factor 1 (TFF1) promotes gemcitabine resistance through chemokine receptor CXCR4 in Pancreatic Ductal… DOI 10.1016/j.canlet.2024.217097↗
    • Paper SUMO Modification of PAF1/PD2 Enables PML Interaction and Promotes Radiation Resistance in Pancreatic Ductal Adenocarci… DOI 10.1128/mcb.00135-21↗
14. Kavita B. Mallya · 3 shared papers, 2022–2026 · strength 0.50
    • Paper Targeting the DDX3/PAF1 axis enhances chemotherapy efficacy in pancreatic ductal adenocarcinoma. DOI 10.1016/j.canlet.2026.218276↗
    • Paper MUC16 Promotes Liver Metastasis of Pancreatic Ductal Adenocarcinoma by Upregulating NRP2-Associated Cell Adhesion. DOI 10.1158/1541-7786.mcr-21-0888↗
    • Paper Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in panc… DOI 10.1038/s41388-022-02493-6↗
15. Venkatesh Varadharaj · 2 shared papers, 2026 · strength 0.49
    • Paper Targeting the DDX3/PAF1 axis enhances chemotherapy efficacy in pancreatic ductal adenocarcinoma. DOI 10.1016/j.canlet.2026.218276↗
    • Paper SLC22A3/OCT3 drives serotonin-mediated stemness in pancreatic cancer. DOI 10.1016/j.celrep.2026.117387↗
16. Zahraa Wajih Alsafwani · 2 shared papers, 2026 · strength 0.49
    • Paper Targeting the DDX3/PAF1 axis enhances chemotherapy efficacy in pancreatic ductal adenocarcinoma. DOI 10.1016/j.canlet.2026.218276↗
    • Paper SLC22A3/OCT3 drives serotonin-mediated stemness in pancreatic cancer. DOI 10.1016/j.celrep.2026.117387↗
17. Rama Krishna Nimmakayala · 4 shared papers, 2021–2022 · strength 0.47
    • Paper MUC16 Promotes Liver Metastasis of Pancreatic Ductal Adenocarcinoma by Upregulating NRP2-Associated Cell Adhesion. DOI 10.1158/1541-7786.mcr-21-0888↗
    • Paper Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic duct… DOI 10.1016/j.canlet.2022.215922↗
    • Paper SUMO Modification of PAF1/PD2 Enables PML Interaction and Promotes Radiation Resistance in Pancreatic Ductal Adenocarci… DOI 10.1128/mcb.00135-21↗
18. Satyanarayana Rachagani · 3 shared papers, 2021–2024 · strength 0.40
    • Paper Connectivity mapping-based identification of pharmacological inhibitor targeting HDAC6 in aggressive pancreatic ductal … DOI 10.1038/s41698-024-00562-5↗
    • Paper Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in panc… DOI 10.1038/s41388-022-02493-6↗
    • Paper Secretory Mucin 5AC Promotes Neoplastic Progression by Augmenting KLF4-Mediated Pancreatic Cancer Cell Stemness. DOI 10.1158/0008-5472.can-20-1293↗
19. Sophia G. Kisling · 2 shared papers, 2023–2024 · strength 0.39
    • Paper Secretory Trefoil Factor 1 (TFF1) promotes gemcitabine resistance through chemokine receptor CXCR4 in Pancreatic Ductal… DOI 10.1016/j.canlet.2024.217097↗
    • Paper A Novel HOXA10-Associated 5-Gene-Based Prognostic Signature for Stratification of Short-term Survivors of Pancreatic Du… DOI 10.1158/1078-0432.ccr-23-0825↗
20. Sakthivel Muniyan · 3 shared papers, 2021–2022 · strength 0.35
    • Paper MUC16 Promotes Liver Metastasis of Pancreatic Ductal Adenocarcinoma by Upregulating NRP2-Associated Cell Adhesion. DOI 10.1158/1541-7786.mcr-21-0888↗
    • Paper SUMO Modification of PAF1/PD2 Enables PML Interaction and Promotes Radiation Resistance in Pancreatic Ductal Adenocarci… DOI 10.1128/mcb.00135-21↗
    • Paper Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in panc… DOI 10.1038/s41388-022-02493-6↗
21. Geoffrey A. Talmon · 2 shared papers, 2022–2026 · strength 0.34
    • Paper SLC22A3/OCT3 drives serotonin-mediated stemness in pancreatic cancer. DOI 10.1016/j.celrep.2026.117387↗
    • Paper Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in panc… DOI 10.1038/s41388-022-02493-6↗
22. Apar Kishor Ganti · 2 shared papers, 2022–2024 · strength 0.32
    • Paper Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma. DOI 10.1016/j.drup.2024.101146↗
    • Paper Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in panc… DOI 10.1038/s41388-022-02493-6↗
23. Rahat Jahan · 2 shared papers, 2021–2024 · strength 0.30
    • Paper Secretory Trefoil Factor 1 (TFF1) promotes gemcitabine resistance through chemokine receptor CXCR4 in Pancreatic Ductal… DOI 10.1016/j.canlet.2024.217097↗
    • Paper Secretory Mucin 5AC Promotes Neoplastic Progression by Augmenting KLF4-Mediated Pancreatic Cancer Cell Stemness. DOI 10.1158/0008-5472.can-20-1293↗
24. Subodh M. Lele · 1 shared paper, 2026 · strength 0.26
    • Paper Targeting the DDX3/PAF1 axis enhances chemotherapy efficacy in pancreatic ductal adenocarcinoma. DOI 10.1016/j.canlet.2026.218276↗
25. Namita Bhyravbhatla · 2 shared papers, 2022 · strength 0.24
    • Paper MUC16 Promotes Liver Metastasis of Pancreatic Ductal Adenocarcinoma by Upregulating NRP2-Associated Cell Adhesion. DOI 10.1158/1541-7786.mcr-21-0888↗
    • Paper Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in panc… DOI 10.1038/s41388-022-02493-6↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.